Keyphrases
ABT-737
100%
Anti-apoptosis
11%
Antiproliferative Activity
11%
Antitumor Activity
11%
Antitumor Effect
11%
Apoptosis
22%
Apoptosis Assay
11%
Apoptosis Induction
100%
Apoptotic Cell Death
11%
B-cell Lymphoma 2 (Bcl-2)
22%
Bcl-2 Inhibitor
100%
Bcl-xL
11%
Bcl-xL Inhibitor
11%
Caspase Activation
11%
Cell Apoptosis
11%
Cell Viability Assay
22%
Clinically Significant
11%
Combination Index
11%
Cytotoxicity
22%
Direct Engagement
11%
Dose Effect
11%
Drug Interactions
11%
Effective Approach
11%
Flow Cytometric
11%
Gastrointestinal Stromal Tumor
44%
Gastrointestinal Stromal Tumor Cells
100%
IC50
11%
Imatinib
100%
Imatinib Mesylate
100%
Imatinib Resistance
44%
Immunoblotting
11%
Induced Apoptosis
11%
Isobologram Analysis
22%
Life Cycle Analysis
11%
Monotherapy
11%
Morphological Changes
11%
Nuclear Morphology
11%
PARP Cleavage
11%
Patient Management
11%
Pro-apoptotic
11%
Proliferation Apoptosis
11%
Resistant Cells
11%
Stromal Progression
11%
Stromal Resistance
11%
Synergism
11%
Synergistic Drug Combination
11%
Synergistic Induction
100%
Tumor Progression
11%
Tumor Resistance
11%
Biochemistry, Genetics and Molecular Biology
Antineoplastic Activity
6%
Apoptosis
6%
Apoptosis Assay
6%
Bcl-2
100%
Bcl-xL
13%
Caspase
6%
Cell Viability
13%
Cell-Cycle Analysis
6%
Cytotoxicity
13%
Drug Interaction
6%
IC50
6%
Imatinib
100%
Immunoblotting
6%
Isobologram
13%
Morphology
6%
Poly ADP Ribose Polymerase
6%
Pharmacology, Toxicology and Pharmaceutical Science
Antitumor Activity
6%
Apoptosis Assay
6%
Caspase
6%
Cell Viability
13%
Cytotoxicity
13%
Drug Interaction
6%
Gastrointestinal Stromal Tumor
100%
IC50
6%
Imatinib
100%
Monotherapy
6%
Synergism
6%
Tumor Growth
6%
Tumor Resistance
6%
Viability Assay
6%
Western Blot
6%